following a full submission:
desmopressin (Noqdirna®) is not recommended for use within NHS Scotland.
Indication under review: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
Two phase III, placebo-controlled studies demonstrated that desmopressin, at licensed doses over three months, significantly reduced the mean number of nocturnal voids and resulted in higher proportions of responders compared with placebo, in patients with nocturia.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
|Drug Name:||desmopressin (Noqdirna)|
|SMC Drug ID:||1218/17|
|Manufacturer:||Ferring Pharmaceuticals Ltd|
|Indication:||symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.|
|Sub Category:||6.5 Hypothalamic and pituitary hormones and anti-oestrogens|
|Submission Type:||Full submission|
|Date Advice Published:||13 February 2017|